APA (7th ed.) Citation

Deng, C., Cao, Y., Deng, Y., Chun, L., & Xinliang, S. (2026). Preoperative Co‐Mutation of BRAFV600E and TERT Promoter Predicts Tumor Aggressiveness and Recurrence‐Free Survival in Papillary Thyroid Carcinoma. Cancer Medicine, 15(6), 1. https://doi.org/10.1002/cam4.72029

Chicago Style (17th ed.) Citation

Deng, Chang, Yijia Cao, Yuping Deng, Lin Chun, and Su Xinliang. "Preoperative Co‐Mutation of BRAFV600E and TERT Promoter Predicts Tumor Aggressiveness and Recurrence‐Free Survival in Papillary Thyroid Carcinoma." Cancer Medicine 15, no. 6 (2026): 1. https://doi.org/10.1002/cam4.72029.

MLA (9th ed.) Citation

Deng, Chang, et al. "Preoperative Co‐Mutation of BRAFV600E and TERT Promoter Predicts Tumor Aggressiveness and Recurrence‐Free Survival in Papillary Thyroid Carcinoma." Cancer Medicine, vol. 15, no. 6, 2026, p. 1, https://doi.org/10.1002/cam4.72029.